Stifel analyst Thomas Stephan resumed coverage of Globus Medical (GMED) with a Hold rating and $64 price target Respondents in the firm’s spine surgeon survey expect moderating 2026 spine procedure growth and as an industry leader, Globus would likely be among the most susceptible to any market softness, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED: